Breast Cancer

  • Approximately 70% to 80% of all breast cancers are hormone receptor–positive (HR+), with tumor cells expressing either the estrogen receptor (ER), progesterone receptor (PR), or both.
  • Testing for human epidermal growth receptor 2 (HER2) protein overexpression and / or HER2 gene amplification is undertaken at diagnosis to guide treatment decisions
  • More than 80% of HR+ tumors are HER2-negative (HER2-) so that HR+/HER2- breast cancer is the most common subtype of invasive breast cancer
  • Adjuvant therapy for breast cancer aims to treat micrometastatic disease
  • A cornerstone of treatment for HR+/HER2- breast cancer is adjuvant endocrine therapy (eg, aromatase inhibitors and/or tamoxifen with or without ovarian suppression).
##Arrangoiz #BreastSurgeon

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s